Hot growth stocks: how to invest in Wegovy and other GLP-1 weight-loss drugs

Interested in investing in new weight-loss drugs like Wegovy, Ozempic, and Mounjaro? Here are the key growth stocks to know about.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GLP-1 weight-loss drugs such as Wegovy have been making headlines. Given their health benefits, demand for these drugs is sky-high. Can Wegovy and other GLP-1 drugs be invested in? Absolutely. Here’s a look at some growth stocks that provide exposure to this exciting area of healthcare.

The leader in GLP-1 drugs

When looking for portfolio exposure to GLP-1 drugs, it’s hard to bypass Danish pharmaceutical company Novo Nordisk (NYSE: NVO).

It’s the maker of Wegovy. It also makes Ozempic. This is a diabetes drug that has the same active ingredient as Wegovy and also leads to weight loss. It’s worth noting that Ozempic has only been approved by the US Food and Drug Administration (FDA) for the treatment of diabetes.

Thanks to the success of its weight-loss drugs, Novo Nordisk’s revenues are surging. Revenue is expected to be 27% higher than last year for 2023 after the company raised its guidance on multiple occasions this year.

On the downside however, the stock is now quite expensive. At present, it trades at 44 times this year’s forecast earnings and 37 times next year’s.

Personally, I’d be a little hesitant about buying in that multiple as it doesn’t leave much room for error.

FDA approval coming?

The other major player in the GLP-1 space is US pharma giant Eli Lilly (NYSE: LLY).

It has a diabetes drug called Mounjaro that leads to weight loss. And the FA could approved this product for obesity treatment shortly. Like Wegovy, it has shown to help patients lose a large proportion of their body weight (up to 16%).

Additionally, Eli Lilly is working on a new product called ‘triple G’. This is designed to mimic the action of the GLP-1 hormone and has demonstrated even more powerful effects when it comes to weight loss.

Unfortunately, this stock is very expensive as well. Currently, its forward-looking P/E ratio is 88, falling to 47 using next year’s earnings forecast.

Again, I’d be a little hesitant about buying in at that multiple.

Other weight-loss stocks

Now, while Novo Nordisk and Eli Lilly are the two main companies in the GLP-1 space right now, there are plenty of other growth stocks that offer exposure to the theme.

Ultimately, the weight-loss drug boom could benefit a range of companies including healthcare consumables businesses (Catalent and Thermo Fisher Scientific are two helping Novo Nordisk make Wegovy) and virtual healthcare companies.

One stock I’ve had a nibble at to get some exposure to the theme is LifeMD. It’s a small US virtual healthcare provider that has just launched a new GLP-1-focused weight management programme.

Eligible participants can get access to GLP-1 medications like Wegovy and Ozempic through this programme if it’s deemed clinically appropriate.

LifeMD has said that its weight management programme could be a catalyst for significant growth and enhanced profitability. So I think there’s a lot to be excited about here.

That said, this is a high-risk, speculative stock as the company is tiny and not yet profitable. Given the risk level, I’ve only taken a really small position.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in LifeMD. The Motley Fool UK has recommended Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Growth Shares

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

This once-great FTSE 250 UK fashion retailer is down 47%, so is it time for me to buy?

A formerly iconic UK fashion brand, this FTSE 250 firm has fallen out of favour. But it has a new…

Read more »

Investing Articles

Where might the Rolls-Royce share price be in 12 months? Here’s what the experts say

The Rolls-Royce share price has more than doubled since November 2023. But analysts have a wide range of opinions as…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

As Shell’s share price continues to drift lower despite strong Q3 results, should I buy more?

Shell’s share price is down 14% from its one-year traded high, despite strong recent results, leaving the shares looking undervalued…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Growth Shares

10,000 or 6,000? Here’s where I think the stock market is heading in 2025

Jon Smith weighs up both sides of the argument as to where the stock market could head next year, along…

Read more »